Galectin Therapeutics’ (GALT) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Galectin Therapeutics (NASDAQ:GALT) in a research report released on Friday morning,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for Galectin Therapeutics’ FY2027 earnings at $1.25 EPS and FY2028 earnings at $3.39 EPS.

Separately, StockNews.com downgraded shares of Galectin Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th.

Galectin Therapeutics Price Performance

GALT stock opened at $2.77 on Friday. The firm has a market capitalization of $172.52 million, a P/E ratio of -3.79 and a beta of 0.62. Galectin Therapeutics has a 52-week low of $1.55 and a 52-week high of $4.27. The company’s 50 day simple moving average is $2.69 and its 200-day simple moving average is $2.61.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC boosted its stake in shares of Galectin Therapeutics by 2.5% during the 3rd quarter. Geode Capital Management LLC now owns 862,542 shares of the company’s stock valued at $2,372,000 after buying an additional 20,817 shares during the period. Barclays PLC grew its stake in Galectin Therapeutics by 309.0% in the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock valued at $79,000 after purchasing an additional 21,598 shares in the last quarter. Kovitz Investment Group Partners LLC acquired a new position in Galectin Therapeutics in the 3rd quarter worth about $117,000. State Street Corp raised its stake in shares of Galectin Therapeutics by 9.3% during the 3rd quarter. State Street Corp now owns 251,014 shares of the company’s stock worth $690,000 after purchasing an additional 21,399 shares in the last quarter. Finally, Gladstone Institutional Advisory LLC acquired a new stake in shares of Galectin Therapeutics during the 3rd quarter valued at about $60,000. Institutional investors and hedge funds own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.